Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,868B 1.93B 1.69B 1.55B 1.43B 2.7B 186B 2.76B 18.6B 7.31B 90.87B 7.24B 7.08B 314B P/E 2026 *
-88.2x
P/E 2027 * -90.8x
Enterprise Value 2,868B 1.93B 1.69B 1.55B 1.43B 2.7B 186B 2.76B 18.6B 7.31B 90.87B 7.24B 7.08B 314B EV / Sales 2026 *
358x
EV / Sales 2027 * 261x
Free-Float
86.03%
Yield 2026 *
-
Yield 2027 * -
07-08 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-29 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
06-01 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-01 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-08 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-02 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
28/08/25 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
14/08/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
15/05/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 day+4.12%
1 week+10.88%
Current month-12.21%
1 month-3.80%
3 months-21.27%
6 months-0.80%
Current year-2.71%
1 week 119,000
Extreme 119000
141,800
1 month 113,000
Extreme 113000
179,400
Current year 111,800
Extreme 111800
217,000
1 year 40,300
Extreme 40300
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 01/02/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 28/03/2022
Director TitleAgeSince
Director/Board Member 59 28/03/2022
Director/Board Member 53 29/03/2021
Chairman 54 01/02/2010
Date Insider Type Main position Quantity % Market Cap.
2/28/25 A Fiscal year

Chief Technology Officer

8,000 0.0433%
2/28/25 A Fiscal year

Director

30,000 0.1625%
Change 5-day change 1-year change 3-year change Capi.($)
+4.12%+10.88%+257.12%+795.15% 1.93B
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+52.85%+71.85% 53.83B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.08%-1.27%+62.72%+244.14% 23.55B
Weighted average by Cap. -2.74%-2.25%+42.12%+148.72%

Financials

2026 *2027 *
Net sales 8B 5.38M 4.7M 4.34M 4M 7.54M 518M 7.7M 51.9M 20.39M 254M 20.2M 19.75M 875M 11B 7.39M 6.47M 5.96M 5.5M 10.36M 712M 10.59M 71.37M 28.04M 349M 27.77M 27.16M 1.2B
Net income -31B -20.83M -18.23M -16.8M -15.5M -29.2M -2.01B -29.85M -201M -79.02M -982M -78.28M -76.54M -3.39B -30B -20.16M -17.64M -16.26M -15M -28.26M -1.94B -28.89M -195M -76.47M -951M -75.75M -74.07M -3.28B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
16/07/26 ₩136,600.00 +4.12% 243,912
15/07/26 ₩131,200.00 +6.06% 221,391
14/07/26 ₩123,700.00 -2.98% 281,711
13/07/26 ₩127,500.00 +3.49% 313,252
10/07/26 ₩123,200.00 +1.48% 270,094
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock